Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Levels of Osteopontin ( SPP1 ), Osteonectin ( SPARC ) and Biglycan ( BGN ) in Acute Myeloid Leukemia Bone Marrow Biopsies Post-Induction Therapy Define the Status of Osteogenic Niche and Show Inverse Correlation with Therapeutic Response

Diana O Treaba, MD, Dennis M Bonal, Anna D Chorzalska, PhD, Christoph Schorl, PhD, Kelsey Hopkins, John L Reagan, MD, Peter Rintels, MD, Peter J Quesenberry, MD, Patrycja M Dubielecka, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142604

Published: 2020

Journal Articles

Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethlators for Acute Myeloid Leukemia

Aryeh Pelcovits, MD, Brianna Bakow, MD, Jozal Waroich, Pamela C Egan, MD, Rabin Niroula, MBBS, Adam J Olszewski, MD, John L Reagan, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-133880

Published: 2020

Journal Articles

Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma

Adam J Olszewski, MD, Anna D Chorzalska, PhD, Max Petersen, Thomas A Ollila, MD, Adam Zayac, MD, Habibe Kurt, MD, Diana O Treaba, MD, John L Reagan, MD, Andrew Hsu, MD, Pamela C Egan, MD, James Butera, MD, William Rafelson, MDMBA, Rabin Niroula, MBBS, John Vatkevich, Jordan Robison, CRA, Ilyas Sahin, MD, Chelsea D Mullins, BS, Patrycja M Dubielecka, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-134757

Published: 2020

Journal Articles

Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study

Thomas A Ollila, MD, James Butera, MD, Pamela C Egan, MD, John L Reagan, MD, Anthony G Thomas, DO, Inna Yakirevich, NP, Kelsey MacKinnon, Jeannine Margolis, Valerie Rosati, Jessica McMahon, RN, Jordan Robison, CRA, Adam J Olszewski, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-134054

Published: 2020

Journal Articles

Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma

Peter Barth, MD, Smith Giri, MBBS, John L. Reagan, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 3155.

https://doi.org/10.1182/blood-2019-121992

Published: 2019

Journal Articles

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Adam Zayac, MD, Pamela C Egan, MD, Thomas A Ollila, MD, Adam J Olszewski, MD, Peter Barth, MD, Matthew I. Quesenberry, MD, James Butera, MD, Loren D. Fast, PhD, Rabin Niroula, MBBS, Peter J. Quesenberry, MD, John L Reagan, MD

Blood (2019) 134 (Supplement_1): 4460.

https://doi.org/10.1182/blood-2019-123789

Published: 2019

Journal Articles

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Adam J Olszewski, MD, Thomas A Ollila, MD, John L. Reagan, MD

Blood (2019) 134 (Supplement_1): 2824.

https://doi.org/10.1182/blood-2019-121841

Published: 2019

Journal Articles

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Adam J Olszewski, MD, Anna D Chorzalska, PhD, Diana O Treaba, MD, John L Reagan, MD, Pamela C Egan, MD, Habibe Kurt, MD, James Butera, MD, William Rafelson, MDMBA, Alexander C Mohler, MD MS, Thomas A Ollila, MD, Rabin Niroula, MBBS, Jordan Robison, CRA, Chelsea D Mullins, BS, Patrycja M Dubielecka, PhD

Blood (2019) 134 (Supplement_1): 2800.

https://doi.org/10.1182/blood-2019-125475

Published: 2019

Journal Articles

Survival Benefits from Antifungal Prophylaxis and a Dedicated Inpatient Malignant Hematology Service during Induction Chemotherapy for Acute Myeloid Leukemia

Andrew Hsu, MD, Robert Matera, MD, John L. Reagan, MD, Dimitrios Farmakiotis, MD

Blood (2019) 134 (Supplement_1): 3436.

https://doi.org/10.1182/blood-2019-122264

Published: 2019

Journal Articles

Evaluating the Incidence of Cardiovascular and Thrombotic Events in Secondary Polycythemia

Clara Mao, BS, Adam J Olszewski, MD, Pamela C Egan, MD, Peter Barth, MD, John L Reagan, MD

Blood (2019) 134 (Supplement_1): 3511.

https://doi.org/10.1182/blood-2019-122943

Published: 2019

Journal Articles

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Adam J Olszewski, MD, Peter Barth, MD, John L. Reagan, MD

Blood (2018) 132 (Supplement 1): 709.

https://doi.org/10.1182/blood-2018-99-110739

Published: 2018

Journal Articles

Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations

Adam J Olszewski, MD, Anna Dorota Chorzalska, PhD, Annette S. Kim, MD PhD, Peter J. Quesenberry, MD, Mary L Lopresti, DO, Mary Anne Fenton, MD, John L. Reagan, MD, James Butera, MD, Ilyas Sahin, MD, Celine Hamel, CRA, Jordan Robison, CRA, Max Petersen, Patrycja Dubielecka, PhD

Blood (2018) 132 (Supplement 1): 3841.

https://doi.org/10.1182/blood-2018-99-111436

Published: 2018

Journal Articles

Using Machine Learning to Classify the "Goodness" of Hmsc-Derived and AML-Derived EV's

Chibuikem Chukwudalu Nwizu, Lorin Crawford, PhD, Theo Borgovan, MD BS, Sicheng Wen, MD PhD, Mark S Dooner, Pamela C Egan, MD, John L. Reagan, MD, Adam J Olszewski, MD, Laura R Goldberg, MD PhD, Peter J. Quesenberry, MD

Blood (2018) 132 (Supplement 1): 5244.

https://doi.org/10.1182/blood-2018-99-120183

Published: 2018

Journal Articles

Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia

Thomas A Ollila, MD, Adam Zayac, MD, Adam J Olszewski, MD, Ross W Hilliard, MD, David Riley, MD, Ari Pelcovits, MD, Matthew R. Austin, MD, Matthew Keane, John L. Reagan, MD

Blood (2018) 132 (Supplement 1): 2442.

https://doi.org/10.1182/blood-2018-99-110375

Published: 2018

Journal Articles

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Peter Martin, FRCPC, MD MS, Nancy L. Bartlett, MD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD MSc, Jeffrey A. Jones, MD MPH, James Drew, MA, Chengqing Wu, PhD, Leandro Cerchietti, MD, John P. Leonard, MD

Blood (2018) 132 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2018-99-114438

Published: 2018

Journal Articles

Diagnosis-to-Treatment Interval As a Prognostic Factor in Aggressive T-Cell Lymphomas

Thomas A Ollila, MD, John L. Reagan, MD, Adam J Olszewski, MD

Blood (2018) 132 (Supplement 1): 2913.

https://doi.org/10.1182/blood-2018-99-110231

Published: 2018

Journal Articles

Outcomes Associated with Antimicrobial Use during High Dose Cytarabine Consolidation in Acute Myeloid Leukemia

Colin Vale, MD, Dimitrios Farmakiotis, MD, Pamela C Egan, MD, Randall Ingham, MD, John L. Reagan, MD

Blood (2018) 132 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2018-99-110175

Published: 2018

Journal Articles

Loss of Abelson Interactor-1 Is Linked to Inflammatory Hematopoiesis and Accelerated Aging of Hematopoietic System

Anna Dorota Chorzalska, PhD, John Morgan, PhD, Max Petersen, Diana O Treaba, MD, Adam J Olszewski, MD, John L. Reagan, MD, Patrycja Dubielecka, PhD

Blood (2018) 132 (Supplement 1): 1285.

https://doi.org/10.1182/blood-2018-99-118393

Published: 2018

Journal Articles

Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia

Thomas Ollila, MD, Adam J Olszewski, MD, Peter J. Quesenberry, MD, Matthew I. Quesenberry, MD, James Butera, MD, John L. Reagan, MD

Blood (2017) 130 (Supplement 1): 1428.

https://doi.org/10.1182/blood.V130.Suppl_1.1428.1428

Published: 2017

Journal Articles

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Peter Martin, MD, Nancy L. Bartlett, MD, Ildefonso Ismael Rodriguez Rivera, MD, Maria Revuelta, PhD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD, Lei Zhang, MD, Merry Zhai, BS, Chengqing Wu, PhD, John P. Leonard, MD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 192.

https://doi.org/10.1182/blood.V130.Suppl_1.192.192

Published: 2017

NARROW

Levels of Osteopontin ( SPP1 ), Osteonectin ( SPARC ) and Biglycan ( BGN ) in Acute Myeloid Leukemia Bone Marrow Biopsies Post-Induction Therapy Define the Status of Osteogenic Niche and Show Inverse Correlation with Therapeutic Response

Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethlators for Acute Myeloid Leukemia

Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma

Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study

Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Survival Benefits from Antifungal Prophylaxis and a Dedicated Inpatient Malignant Hematology Service during Induction Chemotherapy for Acute Myeloid Leukemia

Evaluating the Incidence of Cardiovascular and Thrombotic Events in Secondary Polycythemia

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations

Using Machine Learning to Classify the "Goodness" of Hmsc-Derived and AML-Derived EV's

Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Diagnosis-to-Treatment Interval As a Prognostic Factor in Aggressive T-Cell Lymphomas

Outcomes Associated with Antimicrobial Use during High Dose Cytarabine Consolidation in Acute Myeloid Leukemia

Loss of Abelson Interactor-1 Is Linked to Inflammatory Hematopoiesis and Accelerated Aging of Hematopoietic System

Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only